2010
Hyperglycemia on admission predicts larger infarct size in patients undergoing percutaneous coronary intervention for acute ST-segment elevation myocardial infarction
Cruz-Gonzalez I, Chia S, Raffel O, Sanchez-Ledesma M, Senatore F, Wackers F, Nathan D, Jang I. Hyperglycemia on admission predicts larger infarct size in patients undergoing percutaneous coronary intervention for acute ST-segment elevation myocardial infarction. Diabetes Research And Clinical Practice 2010, 88: 97-102. PMID: 20083319, DOI: 10.1016/j.diabres.2010.01.001.Peer-Reviewed Original ResearchConceptsST-segment elevation myocardial infarctionPrimary percutaneous coronary interventionAcute ST-segment elevation myocardial infarctionPrimary PCILarger infarct sizeElevation myocardial infarctionPercutaneous coronary interventionInfarct sizeCoronary interventionMyocardial infarctionDay 5Final TIMI 3 flowTIMI 3 flowMultivariate linear regression analysisSingle photon emissionAdmission correlateSTEMI patientsBaseline characteristicsDiabetic statusHyperglycemia groupIndependent predictorsHyperglycemiaPatientsLinear regression analysisAdmission
2008
Association of Leukocyte and Neutrophil Counts With Infarct Size, Left Ventricular Function and Outcomes After Percutaneous Coronary Intervention for ST-Elevation Myocardial Infarction
Chia S, Nagurney J, Brown D, Raffel O, Bamberg F, Senatore F, Wackers F, Jang I. Association of Leukocyte and Neutrophil Counts With Infarct Size, Left Ventricular Function and Outcomes After Percutaneous Coronary Intervention for ST-Elevation Myocardial Infarction. The American Journal Of Cardiology 2008, 103: 333-337. PMID: 19166685, DOI: 10.1016/j.amjcard.2008.09.085.Peer-Reviewed Original ResearchConceptsPrimary percutaneous coronary interventionLeft ventricular ejection fractionPrimary PCIST-segment elevation myocardial infarctionElevation myocardial infarctionLarger infarct sizePercutaneous coronary interventionInfarct sizeNeutrophil countMyocardial infarctionElevated leukocytesLeukocyte countCardiac eventsCoronary interventionFirst ST-segment elevation myocardial infarctionAcute Myocardial Infarction StudyST-elevation myocardial infarctionAssociation of leukocytesComposite cardiac eventsIntracellular calcium modulatorsLeft Ventricular SalvageAdverse cardiac eventsElevated leukocyte countPlacebo-controlled trialMyocardial Infarction StudyUtility of Cardiac Biomarkers in Predicting Infarct Size, Left Ventricular Function, and Clinical Outcome After Primary Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction
Chia S, Senatore F, Raffel O, Lee H, Wackers F, Jang I. Utility of Cardiac Biomarkers in Predicting Infarct Size, Left Ventricular Function, and Clinical Outcome After Primary Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction. JACC Cardiovascular Interventions 2008, 1: 415-423. PMID: 19463339, DOI: 10.1016/j.jcin.2008.04.010.Peer-Reviewed Original ResearchMeSH KeywordsAgedAngioplasty, Balloon, CoronaryBenzenesulfonatesBiomarkersCardiovascular AgentsCoronary AngiographyCreatine Kinase, MB FormDisease-Free SurvivalFemaleHumansKaplan-Meier EstimateMaleMiddle AgedMyocardial InfarctionMyocardiumPiperazinesPredictive Value of TestsProportional Hazards ModelsProspective StudiesRisk AssessmentStroke VolumeTime FactorsTomography, Emission-Computed, Single-PhotonTreatment OutcomeTroponin ITroponin TUnited StatesVentricular Function, LeftConceptsST-segment elevation myocardial infarctionPrimary percutaneous coronary interventionPrimary PCIElevation myocardial infarctionPercutaneous coronary interventionInfarct sizeClinical outcomesMyocardial infarctionCardiac biomarkersCoronary interventionCreatine kinaseCK-MBLarge ST-segment elevation myocardial infarctionTroponin TIntracellular calcium modulatorsLarger infarct sizeVentricular ejection fractionCardiac biomarker levelsLeft ventricular functionComposite clinical eventsTime-concentration curveEVOLVE trialLower LVEFAdverse eventsEjection fraction
2007
A randomized, double-blind, placebo-controlled study of the safety and efficacy of intravenous MCC-135 as an adjunct to primary percutaneous coronary intervention in patients with acute myocardial infarction: Evaluation of MCC-135 for left ventricular salvage in acute myocardial infarction (EVOLVE)
Jang I, Weissman N, Picard M, Zile M, Pettigrew V, Shen S, Tatsuno J, Hibberd M, Tzivoni D, Wackers F, Investigators T. A randomized, double-blind, placebo-controlled study of the safety and efficacy of intravenous MCC-135 as an adjunct to primary percutaneous coronary intervention in patients with acute myocardial infarction: Evaluation of MCC-135 for left ventricular salvage in acute myocardial infarction (EVOLVE). American Heart Journal 2007, 155: 113.e1-113.e8. PMID: 18082500, DOI: 10.1016/j.ahj.2007.08.020.Peer-Reviewed Original ResearchMeSH KeywordsAgedAngioplasty, Balloon, CoronaryBenzenesulfonatesCardiac CatheterizationCombined Modality TherapyCoronary AngiographyDose-Response Relationship, DrugDouble-Blind MethodDrug Administration ScheduleElectrocardiographyFemaleFollow-Up StudiesHumansInfusions, IntravenousMaleMiddle AgedMyocardial InfarctionPiperazinesProbabilityReference ValuesRisk AssessmentSalvage TherapyStroke VolumeSurvival RateTreatment OutcomeVentricular Function, LeftConceptsPrimary percutaneous coronary interventionLeft ventricular ejection fractionST-elevation myocardial infarctionPrimary PCIMCC-135Percutaneous coronary interventionAcute myocardial infarctionInfarct sizeMyocardial infarctionDay 5Coronary interventionClinical outcomesCalcium overloadPreservation of LVEFAcute ST-elevation myocardial infarctionEnd pointTarget populationComposite clinical outcomeLeft Ventricular SalvagePlacebo-controlled studyPrimary end pointSecondary end pointsLow-dose groupVentricular ejection fractionHigh-dose group
2005
A Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Intravenous MCC-135 as an Adjunct to Primary Percutaneous Coronary Intervention in Patients with Acute Myocardial Infarction: Rationale and Design of the Evaluation of MCC-135 for Left Ventricular Salvage in Acute MI (EVOLVE) Study
Jang I, Pettigrew V, Picard M, Kowey P, Demmel V, Zile M, Tatsuno J, Wackers F, Hibberd M. A Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Intravenous MCC-135 as an Adjunct to Primary Percutaneous Coronary Intervention in Patients with Acute Myocardial Infarction: Rationale and Design of the Evaluation of MCC-135 for Left Ventricular Salvage in Acute MI (EVOLVE) Study. Journal Of Thrombosis And Thrombolysis 2005, 20: 147-153. PMID: 16261287, DOI: 10.1007/s11239-005-3267-4.Peer-Reviewed Original ResearchMeSH KeywordsAcute DiseaseAdolescentAdultAngioplasty, Balloon, CoronaryBenzenesulfonatesCalciumDouble-Blind MethodEchocardiographyHumansMaleMiddle AgedMuscle CellsMyocardial InfarctionMyocardial Reperfusion InjuryNecrosisPiperazinesRadiographyTomography, Emission-Computed, Single-PhotonVentricular Function, LeftConceptsPrimary percutaneous coronary interventionST-elevation myocardial infarctionLeft Ventricular SalvageElevation myocardial infarctionPlacebo-controlled clinical trialMCC-135Percutaneous coronary interventionIntracellular calcium overloadMyocardial infarctionPost-myocardial infarctionVentricular functionCalcium overloadEVOLVE studyCoronary interventionAdjunct therapyInfarct sizeClinical trialsPrimary PCIAcute ST-elevation myocardial infarctionMI studiesVentricular ejection fractionSerum cardiac markersAcute myocardial infarctionEarly clinical studiesMyocardial infarction size